Publications 2025

  1. Viremia does not independently predict cardiovascular disease in people with HIV: a RESPOND cohort study. Elvstam O, Ryom L, Neesgaard B, Tau L, Günthard H F, Zangerle R, Vehreschild J J, Wit F, Sönnerborg A, Kovari H, Abutidze A, Petoumenos K, Jaschinski N, Hosein S, Bogner J, Grabmeier-Pfistershammer K, Garges H, Rooney J, Young L, Law M, Kirk O for the RESPOND Study Group.
    Open Forum Infectious Diseases 2025. Jan 13;12(2):ofaf016.  Abstract

  2. A simple tool to evaluate the effectiveness of HIV care for settings with gaps in data availability (ESTIHIV). Raben D, Jakobsen M L, Trajanovska J, Kowalska J, Vassilenko A, Dragas S, Harxhi A, Dragovic G J, Jaschinski N, Neesgaard B, Hjorth-Larsen K, Garges H, Gallant J, Lundgren J D, Philips A, Cambiano V, Yazdanpanah Y and Mocroft A.
    PLOS One 2025. Jan 29;20(1):e0316794.  Abstract

  3. Incident tuberculosis in people with HIV across Europe from 2012-2022: incidence rates, risk factors, and regional differences in a multicentre cohort study​. Kraef C, Roen A, Podlekareva D, Bakowska E, Nemeth J, Knappik M, Payen M-C, Wit F, Mussini C, d’Arminio Monforte11 A, Castagna A, Chkhartishvili N, Neesgaard B, Jaschinski1 N, Volny Anne A, Borodulina E, Ballief M, Wallner E, Israelski D, Garges H, Mocroft A, Kirk O and the RESPOND Study Group.
    European Respiratory Journal 2025. Feb 20:2401904.   Abstract

  4. Authors reply to “HIV-TB risk factor assessment in Europe: methodological considerations and clinical implications“ Kraef C, Ryom L, Kirk O writing group and the RESPOND study group
    European Respiratory Journal, 2025 (in press) 

  5. Risk of cancer in people with HIV experiencing varying degrees of immune recovery with sustained virological suppression on antiretroviral treatment for more than 2 years: an international, multicentre, observational cohort. Han WM, Ryom L, Sabin C, Greenberg L, Cavassini M, Egle A, Duvivier C, Wit F, Mussini C, d'Arminio Monforte A, Castagna A, Miro JM, van der Valk M, Bonnet F, Pradier C, Skocic M, Matulionyte R, Stöckle M, Jaschinski N, Timiryasova A, Tallada J, Rogatto FP, Vannappagari V, Young LA, Lundgren JD, Petoumenos K, Hoy JF.
    Clinical Infectious Diseases 2025. May 15:ciaf248.  Abstract

  6. Mortality using raltegravir versus other integrase strand-transfer inhibitors in people with HIV in Europe and Australia: a prospective multicentre study Tusch E, Ryom L, Hoffmann C, Degen O, Zangerle R, Günthard HF, Wit F, Mussini C, Castagna A, Martin C, Giacomelli A, Vehreschild JJ, Begovac J, Vannappagari V, Rooney J, Mendes SDS, Tallada J, Kowalska J, Wallner E, Kusejko K, Jaschinski N, Lundgren J, Peters L, Reekie J
    eClinicalMedicine 2025 Sep 20:89:103521  Abstract

  7. Use of Preventive Measures for Cardiovascular Disease in People with HIV N. Jaschinski, B. Neesgaard, F. Wit, M. Van der Valk, J. Kowalska, A.L. Ridolfo, H. F. Günthard, M. Stöckle, E. Wallner, P. Nowak, A. Castagna, A. d’Arminio Monforte, K. Petoumenos, J. Hoy, S. Hosein, J. Lundgren, H. Garges, F. Rogatto, L. Young, L. Peters, A. Mocroft, and L. Ryom on behalf of the RESPOND Study Group*
    Open Forum Infectious Diseases   Abstract

  8. Mortality and Non-Fatal Clinical Outcomes After the Most Common Cancers in People with HIV: A Multicohort Collaboration Timiryasova A, Greenberg L, Domingo P, Tarr PE, Egle A, Martin C, Mussini C, Wit F, Cingolani A, Lehmann C, Castagna A, Petoumenos K, Sabin CA, Bonnet F, Lundgren J, Bottanelli M, Hosein S, Carlander C, Amstutz A, Grabmeier-Pfistershammer K, Garges H, Marongiu A, Young LA, Peters L, Ryom L for the D:A:D and RESPOND Study Groups
    Cancers, 2025. 17(24), 4000. (In press) 

  9. Cancer Burden and Risk Factors Among Women with HIV: A Multi-regional Study from the D:A:D and RESPOND Cohort Collaborations Han WM, Neesgaard B, Knappik M, Cavassini M, Abela IA, Timiryasova A, Greenberg L, Martin C, Mussini C, Wit F, Sabin C, Castagna A, Abutidze A, El-Sadr, W, Bonnet F, Sarcletti M, Carlander C, Hachfeld A, Weis N, Vannappagari V, Rogatto FP, Young LA, Hosein SR, Ryom L, Petoumenos K, on behalf of the D:A:D and RESPOND collaborations
    eClinical Medicine 2025 (in press)